Home/Pipeline/EB06

EB06

Vitiligo

Phase 1Active

Key Facts

Indication

Vitiligo

Phase

Phase 1

Status

Active

Company

Edesa Biotech

About Edesa Biotech

Edesa Biotech is a micro-cap, clinical-stage biotech focused on developing targeted therapies for inflammatory and immune-related diseases, with a dual strategy in acute care and chronic dermatology. Its most advanced assets include EB05, a Phase 3-ready monoclonal antibody for acute lung injury, and EB01, a Phase 2b non-steroidal topical cream for chronic allergic contact dermatitis. The company's strategy is to achieve clinical proof-of-concept and seek strategic partnerships or out-licensing agreements to advance its programs. Despite a challenging financial position, its pipeline addresses significant unmet medical needs with novel mechanisms.

View full company profile

Therapeutic Areas

Immunology Dermatology Acute Care

Other Vitiligo Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
Adimune	Aditxt	Preclinical	Active
Vitiligo Candidate	Teva	Phase 2	Active
Therapeutic Vaccine	2A Pharma	Pre-clinical	Active
CGB-600	CAGE Bio	Phase 2	Active
Vitiligo Trial	Well Pharma Medical Research	Not Specified	Active
Novel Immunology Candidate	Teva Pharmaceutical Industries	Phase 2	Active
Opzelura (ruxolitinib cream)	Incyte	Marketed	Active
Topical Roflumilast Foam 0.3%	Arcutis Biotherapeutics	Phase 2	Proof-of-concept ongoing
SCENESSE® (afamelanotide)	Clinuvel Pharmaceuticals	Phase III	Active (CUV156)